Trevi Therapeutics - TRVI Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TRVI shares.
View TRVI analyst ratings or view top-rated stocks.

3 brokerages have issued 1 year target prices for Trevi Therapeutics' stock. Their TRVI share price forecasts range from $10.00 to $12.00. On average, they expect the company's stock price to reach $10.67 in the next year. This suggests a possible upside of 182.2% from the stock's current price.
View analysts price targets for TRVI or view top-rated stocks among Wall Street analysts.

Trevi Therapeutics' stock was trading at $0.7822 at the beginning of the year. Since then, TRVI shares have increased by 383.3% and is now trading at $3.78.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our TRVI earnings forecast.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.01. During the same quarter last year, the firm earned ($0.41) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), AzurRx BioPharma (AZRX) and Chimerix (CMRX).

(TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

Trevi Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include TPG GP A LLC (11.18%), MAI Capital Management (5.27%), Frazier Life Sciences Management L.P. (3.03%), Renaissance Technologies LLC (0.39%), WealthTrust Axiom LLC (0.24%) and FMR LLC (0.22%). Insiders that own company stock include Enterprise Associates 16 New, Paul Edward Walker and Tpg Gp A, Llc.
View institutional ownership trends.

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TRVI stock can currently be purchased for approximately $3.78.

Trevi Therapeutics (NASDAQ:TRVI) has a market capitalization of $146.23 million. The company earns $-33,940,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The official website for the company is www.trevitherapeutics.com. The company can be reached via phone at (203) 304-2499 or via email at peter.vozzo@westwicke.com.